Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Mid Cap Fund median (34 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 03 Apr 2006 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty Midcap 150 history starts 14 Jan 2019, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | Taurus Mid Cap Fund |
|---|---|
| 03 Apr 2006 | ₹100.00 |
| 14 Dec 2007 | ₹195.59 |
| 26 Aug 2009 | ₹78.51 |
| 08 May 2011 | ₹89.10 |
| 17 Jan 2013 | ₹111.91 |
| 30 Sep 2014 | ₹163.96 |
| 11 Jun 2016 | ₹187.84 |
| 21 Feb 2018 | ₹278.32 |
| 04 Nov 2019 | ₹272.02 |
| 16 Jul 2021 | ₹449.02 |
| 28 Mar 2023 | ₹440.96 |
| 08 Dec 2024 | ₹790.55 |
| 20 Aug 2026 | ₹808.70 |
| Metric | Taurus · Regular NAV ₹128.34 Very High risk ★☆☆☆☆ | Category median Mid Cap Fund · 34 funds |
|---|---|---|
| +4.57% | +8.71% | |
| +11.69% | +18.06% | |
| +13.50% | +16.16% | |
| +14.13% | +15.69% | |
| +10.80% | +16.93% | |
| +12.42% | — | |
| +13.07% | +19.07% | |
| +13.42% | +16.56% | |
| +14.12% | +16.43% | |
| Risk | ||
| 18.39% | 16.23% | |
| 0.28 | 0.74 | |
| 0.37 | 1.00 | |
| -80.94% | -37.39% | |
| Nifty Midcap 150 | — | |
| -5.85% | +0.94% | |
| 0.97 | 0.94 | |
| 83.8% | 96.2% | |
| 106.3% | 90.1% | |
| 2.73% | 2.04% | |
| ₹121.80Cr | ₹7,594Cr | |
| 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹500 | — | |
| 95% | 41% | |
| Anuj Kapil | — | |
| 03 Apr 2006 | — | |
| 37 | — | |
| 45.3% | — | |
| 3.9% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.